Shaping your forecasting.

Welcome to theHub


cancer starts in the tissue, most commonly in the cells that line the milk ducts of the .

cancer affects one in eight women during their lives. No one knows why some women get cancer, but there are many risk factors. Risks that you cannot change include:

Age – the risk rises as you get older
Genes – two genes, BRCA1 and BRCA2, greatly increase the risk. Women who have family members with or ovarian cancer may wish to be tested for the genes.
Personal factors – beginning periods before age 12 or going through menopause after age 55
Symptoms of cancer may include a lump in the , a change in size or shape of the , and discharge from a .

One possible treatment is surgery. It could be a lumpectomy or a mastectomy. Other treatments include radiation therapy, chemotherapy, hormone therapy, and targeted therapy.

Epidemiology Data

Data Available: Incidence Data

Data covers: Males and Females (where applicable) from 2010 to 2050.

Data is split into 5 year age ranges (0-4, 5-9 etc) from 0 to 100+ years, across multiple countries.

Additional sub filters of the data are available. Please see the below pop up box for more information.

Once purchased, the data will be provided in an embedded PowerBI document, in which the data can be filtered and viewed in a way which suits your needs. Raw data can also be downloaded. Below is an example embedded data set which can be filtered in a similar way.

Once the data set has been purchased, please refresh this page. The example data set will then be replaced with actual data.

Please contact us for further information regarding filtering of the data, viewing the data, data available, custom quotes, or anything else.

As well as incidence, data can be filtered by the following attributes:

• 1L / 2L / 3L / 4L metastatic treated (HER2+)
• 1L metastatic treatment eligible (HER2+)
• 1L / 2L treated (Triple neg)
• Adjuvant treated (HER2+)
• Anatomical Location
• BRCA1 Mutation
• BRCA2 Mutation
• Cachexia
• HER2 Status
• Histopathology Carcinoma, NOS
• Histopathology Ductal & Lobular Carcinoma
• Histopathology Ductal Carcinoma
• Histopathology Lobular Carcinoma
• Histopathology Metaplastic
• Histopathology (Pagets)
• Histopathology Other
• Intrinsic Subtype HER2+/HR-
• Intrinsic Subtype Luminal A
• Intrinsic Subtype Luminal B
• Intrinsic Subtype Triple Negative
• Laterality Bilateral Involvement: Origin Unknown
• Laterality Left: Origin of Primary
• Laterality Only One Side Involved: Origin Unknown
• Laterality Paired Site
• Laterality Right: Origin of Primary
• Lymph and Mets Distant
• Lymph and Mets Mets
• Lymph and Mets None
• Lymph and Mets Regional
• Neo and adjuvant treatment eligible (HER2+)
• Neoadjuvant treated (HER2+)
• Oestrogen Receptor Levels Elevated
• Oestrogen Receptor Levels Normal
• PD-L1 Expression
• Progesterone Receptor Levels Elevated
• Progesterone Receptor Levels Normal
• Stage
• Triple negative (total)

Further sub sets are available within the data, please contact us for further information.

Republic of Korea
Russian Federation
Saudi Arabia
South Africa
United Kingdom
United States of America

The more you buy, the more you save*

*discount added at checkout

For all your pharmaceutical
forecasting needs.

theHub is a portal of resources to help you create better forecasting. Courses, templates, software, data and working model examples to get you on the path to better forecasting. Sign up now to get access to a world of interactive content.

About J+D Forecasting.

At J+D it's our mission to simplify the complex nature of pharmaceutical forecasting to help support informed decision making for the future. We are dedicated to helping pharmaceutical and biotech companies use intelligent forecasting solutions to make strategic and operational investment decisions.

For decades, we have crafted bespoke pharmaceutical forecasting models, innovative software and interactive training solutions, each of which has been designed with client needs in mind, allowing businesses to create more intelligent and consistent insights.